ArticleAnnals of medicine and surgery (2012)2025
AI-orchestrated microglial sculptors: pioneering neural homeostasis restoration in 2025.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising global prevalence of neuroinflammatory diseases poses a formidable public health challenge. Central to these pathologies are microglia, the innate immune sentinels of the central nervous system, whose dysregulation contributes significantly to neurodegeneration. In 2025, the convergence of artificial intelligence (AI) and neurobiology is catalyzing a paradigm shift in the restoration of neural homeostasis. This paper presents a forward-looking synthesis of how AI-driven platforms are enabling high-throughput analysis of multi-omics data to identify actionable microglial targets such as TREM2 and CSF1R for therapeutic modulation. Coupled with CRISPR/Cas9 gene editing, AI orchestrates the reprogramming of microglia toward neuroprotective phenotypes, thereby mitigating neuroinflammation and facilitating cognitive recovery in preclinical models. While promising, challenges remain: addressing microglial heterogeneity, establishing reliable biomarkers, ensuring long-term safety, and overcoming ethical and regulatory barriers. This article advocates for multidisciplinary collaboration, infrastructure reform, and equitable policy frameworks to advance AI-orchestrated microglial therapies from research to clinical application, marking a transformative stride in precision neurology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.